openPR Logo
Press release

Precise Analysis on Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Clinical Trials Reviewed for H1, 2017

06-27-2017 12:50 PM CET | Health & Medicine

Press release from: Medical Industry Analysis Reports - MRH

Market Research HUB

Market Research HUB

The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1177500

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 36 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Ophthalmology, Toxicology, Infectious Disease, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Psoriasis, Friedreich Ataxia, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Cardiomyopathy, Chagas Disease (American Trypanosomiasis), Chronic Obstructive Pulmonary Disease (COPD), Diabetic Complications, Diabetic Nephropathy, Medulloblastoma, Neuroblastoma, Radiodermatitis, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Atherosclerosis, Breast Cancer, Cardiovascular Disease, Cerebral Vasospasm, Chronic Kidney Disease (Chronic Renal Failure), Corneal Degeneration, Encephalomyelitis, Huntington Disease, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Metastatic Breast Cancer, Metastatic Melanoma, Mitochondrial Diseases, Neuro Muscular Disorders, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Radiation Injury, Relapsing Remitting Multiple Sclerosis (RRMS), Retinal Degeneration, Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1177500

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report With TOC: http://www.marketresearchhub.com/report/nuclear-factor-erythroid-2-related-factor-2-hebp1-or-nuclear-factor-erythroid-derived-2-like-2-or-nfe2l2-pipeline-review-h1-2017-report.html

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News At: https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Precise Analysis on Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Clinical Trials Reviewed for H1, 2017 here

News-ID: 597698 • Views: 283

More Releases from Medical Industry Analysis Reports - MRH

Global Scoop Stretcher Sales Market Anticipated to Expand at a CAGR of 2.51% bet …
This report studies the Scoop Stretcher Market Status and Outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Scoop Stretcher market by product type and applications/end industries. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1211022 The global Scoop Stretcher market was estimated at 248.06 Million USD in 2016 and is anticipated to expand at
Global Prostaglandin Market Research Report 2017: Market Analysis Revealing Key …
A latest research report titled as ”Global Prostaglandin Market Research Report 2017” has been recently added to the vast portfolio of Market Research Hub (MRH) online research offerings. This report is a professional and in-depth analysis on the present state and future prospect for the global market. It provides valuable information to the industry insiders, potential entrants or investors. It includes an exhaustive enquiry with the reliability of logic and
Global Ingestible Sensors Market Forecasted to Gain Steady Growth at a CAGR of 2 …
The report titled, “Global Ingestible Sensors Market: Analysis By Sensor Type (Temperature, Pressure, Image, pH), By Sensor Application (Medical, Sports & Physical Fitness), By Region, By Country: Opportunities and Forecast (2017-2022)” has covered and analysed the potential of Global Ingestible Sensors Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.
Global Low Trauma/Skin Friendly Adhesives Market Research Report 2017: Industry …
A latest research report titled as ”Global Low Trauma/Skin Friendly Adhesives Market Research Report 2017” has been recently added to the vast portfolio of Market Research Hub (MRH) online research offerings. This report is a professional and in-depth analysis on the present state and future prospect for the global market. It provides valuable information to the industry insiders, potential entrants or investors. It includes an exhaustive enquiry with the reliability

All 5 Releases


More Releases for Factor

Global Antihemophilic Factor Market Research Report
This report studies the global Antihemophilic Factor market status and forecast, categorizes the global Antihemophilic Factor market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report CSL Behring Grifols Octapharma Baxalta Kedrion Geographically, this report studies the top producers and consumers, focuses on
Authentication Software Market Trends, Business Growth, Key Players, Application …
Global Authentication Software Market report provides a detailed market overview of the industry including definitions, classifications, applications, challenges, competitive scenario and industry chain structure. The report also analysis the Authentication Software Market verticals and horizontals, Market Size and CAGR comparison by region. The study objectives are to provide the Authentication Software market trends, future opportunities, SWOT analysis, development, key drivers, top players and their analysis etc. Major regions covered in this
Tumor Necrosis Factor Receptor
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Tumor Necrosis Factor - Pipeline Review, H2 2017” Tumor Necrosis Factor Overview Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Gr …
ReportsWorldwide has announced the addition of a new report title Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2017'; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
UV Protection Factor (UPF) of Textiles
Over exposure to ultraviolet radiation (UVR) from the sun has raised considerable public health concerns. Consumers have an increased awareness of skin cancer, eye damage (such as cataracts) and premature skin aging and as a result they are looking for protection beyond sunscreens such as lotions and creams. Depletion of the ozone layer, which protects the earth’s surface from harmful UVA, UVB and UVC rays, has forced the need for
Factor Power Inc. Celebrates One Year Anniversary
It is with great joy that Factor Power Inc. is pleased to celebrate our one year anniversary, thanks to the loyalty of our valued customers, vendors and resellers. Like most businesses, the first year is always a challenge. We have had many challenges, but with all of them we have come out on top. The openness of our relationships with our customers, vendors and resellers, has made all of these challenges